Please note that this calculator is only applicable
to patients who are:
- HIV-1 positive
- No previous antiretroviral therapy (ART)
- Age 16 years or older
There are two risk calculators:
- risk calculated from start of ART
- risk calculated from 6 months after start of
ART, taking into account initial virological and immunological response
The first calculator estimates the probability of
experiencing a new AIDS defining disease or death by the end of 1, 2,
3, 4 and 5 years after the patient starts antiretroviral therapy. It
also estimates the probability of death from all causes (either HIV
or non-HIV related) for up to five years after the start of therapy.
The second calculator estimates the probability
of experiencing a new AIDS defining disease or death taking into account
the initial response of the patient to ART as measured by their CD4
cell count and HIV-RNA viral load at 6 months after the start of ART.
The probabilities are given for 1, 2, 3, 4 and 5 years after the time
of the 6 month measurements. It also estimates the probability of death
from all causes for up to five years after the time of the 6 month measure
These models have recently been updated based on
recent analyses published in AIDS (AIDS
2007, 21:1185–1197) To use the previous model (prognosis up
to 3 years only) click here
For more information on the methods used in
the calculations and the limitations on their use, please see the corresponding
publications from the ART Cohort Collaboration:
The ART Cohort Collaboration: Prognosis of HIV-1
infected patients up to five years after initiation of HAART: collaborative
analysis of prospective studies. AIDS
2007, 21:1185–1197 Writing committee: Margaret May, Jonathan
Sterne, Caroline Sabin, Dominique Costagliola, Amy Justice, Rodolphe
Thiébaut, John Gill, Andrew Phillips, Peter Reiss, Robert Hogg,
Bruno Ledergerber, Antonella D'Arminio Monforte, Norbert Schmeisser,
Schlomo Staszewski and Matthias Egger
May M, Royston P, Egger M, Justice AC, Sterne JAC,
ART Cohort Collaboration. Development and validation of a prognostic
model for survival time data: application to prognosis of HIV positive
patients treated with antiretroviral therapy. Stat
Med 2003; 23:2375-98
Chene G, Sterne JAC, May M, Costagliola D, Ledergerber
B, Phillips AN et al. Prognostic importance of initial response in HIV-1
infected patients starting potent antiretroviral therapy: analysis of
prospective studies. Lancet
2003; 362(9385):679-86
Egger M, May M, Chene G, Phillips AN, Ledergerber
B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly
active antiretroviral therapy: a collaborative analysis of prospective
studies. Lancet 2002; 360:119-29 (pdf of paper here)